Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
February 4, 2019, InspireMD, Inc. (the “Company”) entered into an amended and restated employment agreement (the “A&R
Employment Agreement”) with Dr. James Barry, Ph.D, its President and Chief Executive Officer. The A&R Employment Agreement
amended, restated and superseded Dr. Barry’s prior employment agreement with the Company, including any amendments thereto.
The
A&R Employment Agreement has an initial term that ends on December 31, 2020 unless earlier terminated. Under the A&R Employment
Agreement, Dr. Barry is entitled to an annual base salary of $400,000. Such amount may be reduced only as part of an overall cost
reduction program that affects all senior executives of the Company and does not disproportionately affect Dr. Barry, so long
as such reductions do not reduce the base salary to less than 90% of the amount set forth above (or 90% of the amount to which
it has been subsequently increased). The base salary will be reviewed annually by the Company’s board of directors (the
“Board”) as part of the Company’s annual compensation review. Dr. Barry is also eligible to receive an annual
bonus in the amount equal to 100% of his base salary upon the achievement of reasonable target objectives and performance goals,
to be determined by the Board in consultation with Dr. Barry. In the event that Dr. Barry’s actual performance exceeds the
goals, the Board may, in its sole discretion, pay Dr. Barry bonus compensation of more than 100% of his base salary. In each case,
the annual bonus shall be payable in accordance with the Company’s annual bonus plan, and the amounts payable under the
annual bonus plan shall be determined by the Board and shall be payable following such fiscal year and no later than two and one-half
months after the end of such fiscal year. In addition, as provided by the A&R Employment Agreement, we agreed to pay for Dr.
Barry’s accrued but unused vacation time through the calendar year 2018 on our next regular payroll date, which amount will
be $32,000.
In
accordance with the A&R Employment Agreement, on February 4, 2019, the Company granted Dr. Barry 2,000,000 shares of restricted
stock, made pursuant to a Restricted Stock Award Agreement. The restricted stock is subject to a three-year vesting period subject
to Dr. Barry’s continued service with the Company, with one-third (1/3rd) of such awards vesting on the first, second and
third anniversary of the grant date. Additionally, upon achievement of certain criteria, Dr. Barry will be eligible to receive
an equity bonus relating to the number of shares of the Company’s common stock equal to 5% of the Company’s shares
outstanding on the date of the grant (inclusive of, rather than in addition to, the shares granted as part of the restricted stock
grant made on February 4, 2019), subject to Board approval, whch shall be comprised of as close as is practicable to 50% stock
options and 50% shares of restricted stock. Dr. Barry is also eligible to receive additional stock-based compensation at the sole
discretion of the Board.
The
A&R Employment Agreement also contains certain noncompetition, no solicitation, confidentiality, and assignment of inventions
requirements for Dr. Barry.
If,
during the term of the A&R Employment Agreement, Dr. Barry’s employment is terminated upon his death or disability,
by Dr. Barry for good reason, or by the Company without cause, Dr. Barry will be entitled to receive, in addition to other unpaid
amounts owed to him (e.g., for base salary and accrued vacation): (i) the pro rata amount of any bonus for the fiscal year of
such termination (assuming full achievement of all applicable goals under the bonus plan) that he would have received had his
employment not been terminated; (ii) a one-time lump sum severance payment equal to $850,000, provided that he executes a release
relating to employment matters and the circumstances surrounding his termination in favor of the Company, its subsidiaries and
their officers, directors and related parties and agents, in a form reasonably acceptable to the Company at the time of such termination;
(iii) vesting of 100% of all unvested stock options, restricted stock shares, restricted stock units, stock appreciation rights
or similar stock based rights granted to Dr. Barry, and lapse of any forfeiture included in such restricted or other stock grants;
(iv) an extension of the term of any outstanding stock options or stock appreciation rights for two years from the date of termination;
(v) to the fullest extent permitted by the Company’s then-current benefit plans, continuation of health, dental, vision
and life insurance coverage for up to 18 months unless Dr. Barry secures coverage from a new employer; and (vi) a cash payment
of $25,000, which Dr. Barry may use for executive outplacement services or an education program. The payment described in (ii)
above will be reduced by any payments received by Dr. Barry pursuant to any of the Company’s employee welfare benefit plans
providing for payments in the event of death or disability. If Dr. Barry continues to be employed by the Company after the term
of the Employment Agreement, unless otherwise agreed by the parties in writing, and Dr. Barry’s employment is terminated
upon his death or disability, by Dr. Barry for good reason, or by the Company without cause, Dr. Barry will be entitled to receive,
in addition to other unpaid amounts owed to him, the payments set forth in (i), (ii) and (iii) above. If the Company does not
extend the term of the A&R Employment Agreement and/or Dr. Barry’s employment is not extended beyond December 31, 2020,
Dr. Barry will be entitled to the payments and benefits set forth in (i)-(vi) above; however, if the Company has offered to extend
the A&R Employment Agreement beyond December 31, 2020 on terms no less favorable than the terms of the A&R Employment
Agreement and Dr. Barry does not agree to such extension, the one-time lump sum severance payment set forth in (ii) above shall
be in the amount of $600,000.
If,
during the term of the A&R Employment Agreement, the Company terminates Dr. Barry’s employment for cause or Dr. Barry
terminates his employment by voluntary termination, Dr. Barry will only be entitled to unpaid and accrued amounts owed to him
through the date of termination and whatever rights, if any, are available to him pursuant to the Company’s stock-based
compensation plans or any award documents related to any stock-based compensation.
Dr.
Barry has no specific right to terminate the A&R Employment Agreement or right to any severance payments or other benefits
solely because of a change in control. However, if within 24 months following a change in control (the “Change in Control
Period”), (a) Dr. Barry terminates his employment for good reason, or (b) the Company terminates his employment without
cause, Dr. Barry will be entitled to the payments and benefits set forth in (i)-(vi) above. Notwithstanding the foregoing, if
the Company terminates Dr. Barry’s employment with the Company prior to the date on which a change in control occurs, and
it is reasonably demonstrated that Dr. Barry’s (i) employment was terminated at the request of an unaffiliated third party
who has taken steps reasonably calculated to effect a change in control or (ii) termination of employment otherwise arose in connection
with or in anticipation of the change in control, then the “Change in Control Period” shall mean the 24 month period
beginning on the date immediately prior to the date of Dr. Barry’s termination of employment with the Company.
Item
5.08 Shareholder Director Nominations.
On
February 4, 2019, the Board established March 21, 2019, as the date for the Company’s 2019 Annual Meeting of Stockholders
(the “Annual Meeting”) and set February 15, 2019 as the record date for the Annual Meeting. Due to the fact that the
date of the Annual Meeting has been changed by more than 30 days from the anniversary date of the 2018 Annual Meeting of Stockholders,
the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder nominations.
In
accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and the Company’s amended and restated bylaws, the deadline for receipt of stockholder proposals or nominations for inclusion
in the Company’s proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than 5:00 p.m., Eastern
Time, February 19, 2019. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and
regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Company’s amended
and restated bylaws.